Survodutide vs Tirzepatide

Survodutide is an experimental drug that targets both glucagon and GLP-1 receptors, but it hasn’t been approved for any treatments yet. Tirzepatide, sold as Mounjaro or Zepbound, is an FDA-approved drug that works on GIP and GLP-1 receptors and is used to treat type 2 diabetes, obesity, and obstructive sleep apnea. The main difference is that survodutide is still in development, while tirzepatide is already on the market with multiple brand names.

AI summary of the sources below.